<DOC>
	<DOCNO>NCT02541045</DOCNO>
	<brief_summary>The aim study evaluate efficacy metadoxine therapy patient biopsy-proven non-alcoholic steatohepatitis .</brief_summary>
	<brief_title>Clinical Trial Evaluate Efficacy Metadoxine Therapy Patients With Non-alcoholic Steatohepatitis</brief_title>
	<detailed_description>Type design study : A randomized , placebo-controlled , double-blind , clinical trial evaluate efficacy metadoxine therapy patient biopsy-proven nonalcoholic steatohepatitis . Population : Non-diabetic patient nonalcoholic steatohepatitis diagnose liver biopsy `` nonalcoholic fatty liver disease activity score '' ( NAS ) &gt; 3 . Sample size : Considering difference least 30 % group , confidence level 95 % ( two-sided , significance 0.05 ) , statistical power 80 % , additional 20 % possible loss , need 54 patient per group . Variables : Independent : Treatment group ( metadoxine / placebo ) . Dependents : - `` Nonalcoholic fatty liver disease activity score '' ( NAS ) :0 8 - Degree liver steatosis : 0 3 - Degree lobular inflammation : 0 3 - Degree ballooning : 0 2 - Degree fibrosis : 0 2 - Weight : Kg - Body mass index : Kg/m2 - Waist circumference : cm - Serum alanine aminotransferase : U/L - Serum aspartate aminotransferase : U/L Methods : Those meeting selection criterion invite participate study , agree participate must sign consent form randomize placebo metadoxine group . The duration therapy 6 month period second liver biopsy perform assessed improvement liver histology .</detailed_description>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Metadoxine</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<criteria>Nondiabetic patient , Overweight obesity degree I , II III accord WHO criteria ( BMI ≥ 25 ) , With evidence liver steatosis ultrasonography , With biopsyproven nonalcoholic steatohepatitis , ≥ 3 NAS score ( least 1 point liver steatosis , least 1 point lobular inflammation , least 1 point ballooning ) , With without fibrosis liver biopsy , present must ≤ 2 scale 4 , 4 equivalent cirrhosis . Cirrhosis , Diabetes , Heavy alcohol intake ( ≥ 20 g / day ) , ≥ 8 point `` Alcohol Use Disorders Identification Test '' ( AUDIT ) , Acute chronic hepatitis C , Acute chronic hepatitis B , Immunodeficiency acquire syndrome Pregnant woman , In last year , history herbal consumption , total parenteral nutrition , amiodarone , methotrexate , hormonal contraceptive , steroid , tamoxifen , valproic acid drug associate development liver steatosis . Uncontrolled hypothyroidism hyperthyroidism , Any uncontrolled chronic disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>non-alcoholic steatohepatitis</keyword>
	<keyword>metadoxine</keyword>
	<keyword>efficacy</keyword>
	<keyword>therapy</keyword>
</DOC>